Targeting DNA Damage Response in the Radio(Chemo)therapy of Non-Small Cell Lung Cancer.
Targeting DNA Damage Response in the Radio(Chemo)therapy of Non-Small Cell Lung Cancer.
复制标题
靶向DNA损伤反应在非小细胞肺癌放化疗中的应用。
DOI：
10.3390/ijms17060839
复制
发表时间：
2016-05-31
影响因子：
5.6
通讯作者：
Liu ZQ
中科院分区：
文献类型：
--
作者：
Li L;Zhu T;Gao YF;Zheng W;Wang CJ;Xiao L;Huang MS;Yin JY;Zhou HH;Liu ZQ
肺癌因其高发病率和高死亡率而成为世界范围内癌症死亡的主要原因。非小细胞肺癌（non-small cell lung cancer，NSCLC）是最常见的肺癌之一，严重威胁着人类的健康。尽管诊断和综合治疗（包括手术切除、放疗和化疗）有所改善，但非小细胞肺癌患者的总生存率仍然很差。DNA损伤被认为是肺癌发展的主要原因，通常由内在DNA损伤反应机制识别和修复。DNA修复途径在放射（化学）治疗抗性癌症中的作用已成为临床环境中的一个重要领域。同时，有研究表明，遗传和表观遗传因素可以改变DNA损伤的反应和修复，从而导致非小细胞肺癌放化疗疗效的改变。本文就基因多态性和表观遗传因素如miRNA调控和lncRNA调控在非小细胞肺癌放（化）疗后DNA损伤修复中的作用作一综述。这些结果可能为基于个体DNA损伤反应的NSCLC放疗（化疗）提供新的信息。
Lung cancer is the leading cause of cancer death worldwide due to its high incidence and mortality. As the most common lung cancer, non-small cell lung cancer (NSCLC) is a terrible threat to human health. Despite improvements in diagnosis and combined treatments including surgical resection, radiotherapy and chemotherapy, the overall survival for NSCLC patients still remains poor. DNA damage is considered to be the primary cause of lung cancer development and is normally recognized and repaired by the intrinsic DNA damage response machinery. The role of DNA repair pathways in radio(chemo)therapy-resistant cancers has become an area of significant interest in the clinical setting. Meanwhile, some studies have proved that genetic and epigenetic factors can alter the DNA damage response and repair, which results in changes of the radiation and chemotherapy curative effect in NSCLC. In this review, we focus on the effect of genetic polymorphisms and epigenetic factors such as miRNA regulation and lncRNA regulation participating in DNA damage repair in response to radio(chemo)therapy in NSCLC. These may provide novel information on the radio(chemo)therapy of NSCLC based on the individual DNA damage response.